logo

For the Inventor, By the Inventor

Ballwin, MO, United States of America

Joe T Collins

This inventor holds 11 USPTO granted patents. Top assignees: G.d. Searle & Company, Pharmacia Corporation. Active years: 1992-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joe T Collins. Retrieved from https://idiyas.com/inventor/joe-t-collins

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 81.8

Average Co-Inventor Count = 4.1

ph-index = 6

Forward Citations = 86(Granted Patents)


Location History:

  • Manchester, MO (US) (1995 - 1996)
  • Ballwin, MO (US) (1992 - 2005)

Company Filing History:

goldMedal8 out of 1,323 
 
G.d. Searle & Company
 patents
silverMedal3 out of 220 
 
Pharmacia Corporation
 patents

Years Active: 1992-2005

Loading Chart...
11 patents (USPTO):Explore Patents
1. 6900244 - Anilino liver X-receptor modulators (2005-05-31),
2. 6822120 - Sulfone liver X-receptor modulators (2004-11-23),
3. 6451833 - N-substituted (&agr;-imidazolyl-toluyl)pyrrole compounds for treatment of circulatory disorders (2002-09-17),
4. 6100423 - Amino benzenepropanoic acid compounds and derivatives thereof (2000-08-08),
5. 6008368 - Pharmaceutical compositions for treatment of circulatory disorders using (1999-12-28),
6. 5504077 - Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, (1996-04-02),
7. 5451597 - Treatment of circulatory disorders using n-substituted (1995-09-19),
8. 5441950 - Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, (1995-08-15),
9. 5281615 - Cycloheptimidazolone compounds as angiotensin II antagonists for control (1994-01-25),
10. 5187271 - N-substituted (.alpha.-imidazolyl-toluyl) pyrrole compounds for (1993-02-16),
11. 5104891 - Cycloheptimidazolone compounds as angiotensin II antagonists for control (1992-04-14),

Title: The Innovations of Joe T Collins

Introduction

Joe T Collins is a notable inventor based in Ballwin, MO (US), recognized for his contributions to the field of pharmaceutical sciences. With a total of 11 patents to his name, Collins has made significant strides in developing innovative compounds that target liver X-receptors.

Latest Patents

Among his latest patents are the "Anilino liver X-receptor modulators" and "Sulfone liver X-receptor modulators." The former is directed to selective LXR modulators, small molecule compounds corresponding to Formula I, and focuses on a process of treating conditions in mammals that are modulated by LXR using a therapeutically effective dose of a compound of Formula I. Similarly, the latter patent also pertains to selective LXR modulators and outlines a comparable therapeutic approach.

Career Highlights

Throughout his career, Joe T Collins has worked with prominent companies such as G.D. Searle & Company and Pharmacia Corporation. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.

Collaborations

Collins has collaborated with esteemed colleagues, including Philippe R Bovy and Robert E Manning, further enhancing the impact of his innovations in the pharmaceutical industry.

Conclusion

Joe T Collins exemplifies the spirit of innovation in the field of pharmaceuticals, with a strong portfolio of patents that address critical health issues. His work continues to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…